(Q45256935)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

11 December 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Tumor necrosis factor enhances SN38-mediated apoptosis in mesothelioma cells: the role of nuclear factor-kappaB pathway activation (English)

1 reference

11 December 2017

Alfredo Cesario

5

0 references

author name string

Patrizia Russo

1

1 reference

11 December 2017

Alessia Catassi

2

1 reference

11 December 2017

Davide Malacarne

3

1 reference

11 December 2017

Stefano Margaritora

4

1 reference

11 December 2017

Luigi Festi

6

1 reference

11 December 2017

Antonino Mulé

7

1 reference

11 December 2017

Luigi Ferri

8

1 reference

11 December 2017

Pierluigi Granone

9

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

11 December 2017

1 reference

11 December 2017

103

1 reference

11 December 2017

7

1 reference

11 December 2017

1503-1518

1 reference

The pathogenesis of mesothelioma

11 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Chemotherapy for malignant pleural mesothelioma: past results and recent developments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Malignant pleural mesothelioma: time for translational research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Absence of p53 mutations in malignant mesotheliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

High throughput testing of the SV40 Large T antigen binding to cellular p53 identifies putative drugs for the treatment of SV40-related cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Alterations of the p16(INK4) locus in human malignant mesothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

p53: only ARF the story

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

TNF increases camptothecin-induced apoptosis by inhibition of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Phase II trial of topotecan for the treatment of mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Topoisomerase I-mediated DNA damage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20924

7 January 2021

The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/CNCR.20924

Identifiers

DOI

10.1002/CNCR.20924

1 reference

11 December 2017

1 reference